StreetInsider.com News Articles

Form 8-K Climb Bio, Inc. For: Jun 11

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641491.html

Form 8-K Climb Bio, Inc. For: Jun 11

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641491.html

Form 424B5 Climb Bio, Inc.

Fri, 12 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26641199.html

Form 424B5 Climb Bio, Inc.

Fri, 12 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260612/26641199.html

Climb Bio (CLYM) PT Raised to $20 at BTIG

Thu, 11 Jun 2026 12:07:22 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $20.00 (from $19.00) while maintaining a Buy rating.

The analyst comments "Budoprutug (anti-CD19 mAb) delivered meaningful platelet responses in heavily pretreated adult ITP patients in initial Phase 1b data. In the 250mg cohort (n=6, median 38-week follow-up), B cells were depleted >90% by Week 4, mean platelet count rose 111K/µL at Week 24, and 4/6 patients achieved durable responses — including complete, durable responses in 2/4 rituximab-pretreated patients (platelets >100K/µL for 24+ weeks), supporting potential in a high-unmetneed refractory population. Safety was clean across both dose cohorts

Climb Bio (CLYM) PT Raised to $20 at BTIG

Thu, 11 Jun 2026 12:07:22 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $20.00 (from $19.00) while maintaining a Buy rating.

Form 8-K Climb Bio, Inc. For: Jun 11

Thu, 11 Jun 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260611/26632557.html

Form 8-K Climb Bio, Inc. For: Jun 11

Thu, 11 Jun 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20260611/26632557.html

Climb Bio reports initial phase 1b data for budoprutug in blood disorder

Thu, 11 Jun 2026 07:00:32 -0400

Climb Bio Inc. (NASDAQ: CLYM) reported initial data from its phase 1b study of budoprutug, an anti-CD19 monoclonal antibody, for treating primary immune thrombocytopenia. The data were presented at the European Hematology Association Congress in Stockholm.

The study evaluated budoprutug in 15 patients across two dose cohorts: 250 mg (6 patients) and 500 mg (9 patients). Patients had received a median of 6 to 7.5 prior therapies and had disease duration ranging from 0.5 to 40 years.

In the 250 mg cohort, B-cell levels decreased by over 90% by week 4, and mean platelet count increased by 111,000 platelets per microliter at

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Thu, 11 Jun 2026 07:00:00 -0400

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia

Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026

WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an encouraging

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Thu, 11 Jun 2026 07:00:00 -0400

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia

Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026

Form EFFECT Climb Bio, Inc.

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626133.html

Form EFFECT Climb Bio, Inc.

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626133.html

Form 424B3 Climb Bio, Inc.

Tue, 09 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260609/26624044.html

Form 424B3 Climb Bio, Inc.

Tue, 09 Jun 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260609/26624044.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: RA Capital Nexus Fund, L.P.

Mon, 08 Jun 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260608/26618709.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: RA Capital Nexus Fund, L.P.

Mon, 08 Jun 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20260608/26618709.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: Levin Andrew David

Mon, 08 Jun 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260608/26618679.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: Levin Andrew David

Mon, 08 Jun 2026 18:42:00 -0400

si-local-file:///var/storage/secattach/20260608/26618679.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: Drapkin Kimberlee C

Mon, 08 Jun 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260608/26618671.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: Drapkin Kimberlee C

Mon, 08 Jun 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260608/26618671.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: WILLIAMS DOUGLAS E

Mon, 08 Jun 2026 18:37:00 -0400

si-local-file:///var/storage/secattach/20260608/26618666.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: WILLIAMS DOUGLAS E

Mon, 08 Jun 2026 18:37:00 -0400

si-local-file:///var/storage/secattach/20260608/26618666.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: Cumbo Alexander

Mon, 08 Jun 2026 18:35:00 -0400

si-local-file:///var/storage/secattach/20260608/26618665.html

Form 4 Climb Bio, Inc. For: Jun 05 Filed by: Cumbo Alexander

Mon, 08 Jun 2026 18:35:00 -0400

si-local-file:///var/storage/secattach/20260608/26618665.html